Prescription drug price transparency. (SB487)

Introduced By

Sen. Emmett Hanger (R-Mount Solon)

Progress

Introduced
Passed Committee
Passed House
Passed Senate
Signed by Governor
Became Law

Description

Prescription drug price transparency. Requires every manufacturer of a prescription drug that is made available in the Commonwealth and has a wholesale acquisition price of $10,000 or more for a single course of treatment to report to the Commissioner no later than July 1 of each year information related to the cost of developing, manufacturing, and marketing the prescription drug; any changes in the average wholesale price and average wholesale acquisition cost of the prescription drug; the amount of profits derived from sale of the prescription drug; and the total amount of financial assistance provided to consumers of the prescription drug. The bill requires the State Health Commissioner to cause such reports to be published on a website maintained by a nonprofit entity with which the Commissioner has entered into a contract for such purpose and to annually report on such information, in aggregate form, to the Chairmen of the House Committees on Appropriations and on Health, Welfare and Institutions and the Senate Committees on Finance and on Education and Health. Amends § 2.2-3705.5, § 32.1-276.4, of the Code of Virginia. Read the Bill »

Status

01/21/2016: Awaiting a Vote in the Education and Health Committee

History

DateAction
01/12/2016Prefiled and ordered printed; offered 01/13/16 16103856D
01/12/2016Referred to Committee on Education and Health
01/15/2016Impact statement from VDH (SB487)
01/21/2016Assigned Education sub: Health Professions
02/04/2016Committee substitute printed to Web only 16105186D-S1
02/04/2016Continued to 2017 in Education and Health (15-Y 0-N) (see vote tally)

Duplicate Bills

The following bills are identical to this one: HB1113.